Group 1 - The core point of the article is the establishment of a co-CEO system at 加科思-B, with Dr. Wang Yinxiang and Dr. Wang Yi taking on the roles to enhance global strategic planning and market expansion [1][1][1] - Following the announcement, 加科思-B's stock price increased by over 7%, reaching 7.31 HKD with a trading volume of 16.91 million HKD [1][1][1] - The company has signed an agreement with 海松资本 for a capital increase and equity transfer, where 海松资本 will pay a total of 2 billion RMB for an 80% stake in 加科瑞康, allowing 加科思 to focus more on its core oncology business [1][1][1] Group 2 - Dr. Wang Yinxiang will continue to lead the company's global strategy and major decisions, while Dr. Wang Yi will focus on international market development and clinical work [1][1][1] - The divestment of non-core assets is expected to strengthen the company's cash flow and strategic focus in the oncology sector [1][1][1]
港股异动 | 加科思-B(01167)早盘涨超7% 公司设立联席首席执行官制度 此前主动剥离非核心资产